Heterocyclic compounds: as Antidiabetic drugs
DOI:
https://doi.org/10.61114/UJPSR.9.2.2023.32-51Keywords:
Diabetes mellitus, Anti-diabetes, type 2 diabetes mellitus, type 1 diabetes mellitus, heterocyclic moieties, treatmentAbstract
Diabetes can have long-term consequences by causing damage to essential organs, blood vessels, and nerves. Diabetes prevalence continues to climb internationally, with poorer nations bearing the brunt of the burden. Diabetes mellitus is a condition characterised by insufficient glucose management in the blood. Type 1 diabetes, type 2 diabetes, neonatal diabetes, maturity-onset diabetes of the young, gestational diabetes and steroid-induced diabetes are all subtypes. Since sickness is essentially because of the shortfall of insulin, insulin organization through day to day infusions, or an insulin siphon, is the backbone of therapy. Traditional oral drug therapy is described in the paper. In type 2 diabetes mellitus, diet and exercise might be satisfactory medicines, particularly at first. Different treatments might insulin awareness or increment insulin emission by the pancreatic islets. The particular classes for drugs incorporate thiazolidinediones, biguanides, sulfonylureas, dipeptidyl peptidase-IV inhibitors, alpha-glucosidase inhibitors, glucagon like-peptide-1 agonist, sodium-glucose carrier 2 inhibitors and meglitinides. And peer review of many heterocyclic moieties used as synthesis of anti-diabetic compound is described. Heterocyclic moieties like oxazole, thiazole, pyrrole, piperazine and many more are explained for generation of antidiabetic compounds having a significant therapeutic effect their structures are also provided and if structure activity relationship is explained for the heterocyclic compounds mentioned and what functional group changes can be possible for significant antidiabetic effect. As several of the pharmacological candidates mentioned show potential as an effective anti-diabetic chemotherapy, this study provides a platform for future medication design and development targeting diabetes treatment (i.e. optimization by structural derivatization).
References
Organisation, W.H. Diabetes. 2022 [cited 2022 17/01]; Available from: https://www.who.int/health-topics/diabetes#tab=tab_1.
Healthline. Type of Diabetes. 2022 [cited 2022 17/01]; Available from: https://www.healthline.com/health/diabetes/types-of-diabetes.
Preventation, C.f.D.C.a. Gestational Diabetes. 2022 August 10, 2021 [cited 2022 17/01]; Available from: https://www.cdc.gov/diabetes/basics/gestational.html#:~:text=Gestational%20diabetes%20is%20a%20type,pregnancy%20and%20a%20healthy%20baby.
Rochester, U.o.R.M.C. Facts about Diabetes. 2022 [cited 2022 17/01]; Available from: https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=85&contentid=P00335.
Clinic, M. Diabetes. 2022 [cited 2022 17/01]; Available from: https://www.mayoclinic.org/diseases-conditions/diabetes/symptoms-causes/syc-20371444.
Knowler, W.C., et al., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. 2002.
Clinic, C. Diabates Mellitus Treatment. 2022 [cited 2022 21/01]; Available from: https://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/diabetes-mellitus-treatment/.
Marín-Peñalver, J.J., et al., Update on the treatment of type 2 diabetes mellitus. World journal of diabetes, 2016. 7(17): p. 354.
Shingalapur, R.V., et al., Derivatives of benzimidazole pharmacophore: Synthesis, anticonvulsant, antidiabetic and DNA cleavage studies. European journal of medicinal chemistry, 2010. 45(5): p. 1753-1759.
Zou, X.-Q., et al., Furoxan nitric oxide donor coupled chrysin derivatives: synthesis and vasculoprotection. Bioorganic & medicinal chemistry letters, 2011. 21(4): p. 1222-1226.
GILANI, S.J., et al., PROGRESS IN THE PHARMACOLOGICAL POTENTIAL OF OXADIAZOLES: A REVIEW. International Bulletin of Drug Research. 2(1): p. 132-146.
Ashton, W.T., et al., Dipeptidyl peptidase IV inhibitors derived from β-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole, or pyrazole. Bioorganic & medicinal chemistry letters, 2005. 15(9): p. 2253-2258.
Kakkar, S. and B. Narasimhan, A comprehensive review on biological activities of oxazole derivatives. BMC chemistry, 2019. 13(1): p. 1-24.
Kumar, A., et al., Novel 2-aryl-naphtho [1, 2-d] oxazole derivatives as potential PTP-1B inhibitors showing antihyperglycemic activities. European journal of medicinal chemistry, 2009. 44(1): p. 109-116.
Pingali, H., et al., Design and synthesis of novel oxazole containing 1, 3-Dioxane-2-carboxylic acid derivatives as PPAR α/γ dual agonists. Bioorganic & medicinal chemistry, 2008. 16(15): p. 7117-7127.
Raval, P., et al., Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents. Bioorganic & medicinal chemistry letters, 2011. 21(10): p. 3103-3109.
Isomaa, B., A major health hazard: the metabolic syndrome. Life sciences, 2003. 73(19): p. 2395-2411.
Ross, S.A., E.A. Gulve, and M. Wang, Chemistry and biochemistry of type 2 diabetes. Chemical reviews, 2004. 104(3): p. 1255-1282.
group, U., UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients. Metabolism, 1990. 39(9): p. 905-912.
Witters, L.A., The blooming of the French lilac. The Journal of clinical investigation, 2001. 108(8): p. 1105-1107.
Yaron, A., F. Naider, and S. Scharpe, Proline-dependent structural and biological properties of peptides and proteins. Critical reviews in biochemistry and molecular biology, 1993. 28(1): p. 31-81.
Gorrell, M., V. Gysbers, and G. McCaughan, CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scandinavian journal of immunology, 2001. 54(3): p. 249-264.
Gautier, J., et al., Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes & metabolism, 2005. 31(3): p. 233-242.
Mojsov, S., G.C. Weir, and J.F. Habener, Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. The Journal of clinical investigation, 1987. 79(2): p. 616-619.
Nauck, M.A., et al., Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. The Journal of Clinical Endocrinology & Metabolism, 2002. 87(3): p. 1239-1246.
Wettergren, A., et al., Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Digestive diseases and sciences, 1993. 38(4): p. 665-673.
Ji, X., et al., Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors. European journal of medicinal chemistry, 2014. 75: p. 111-122.
Salim, B., Diabetes mellitus and its treatment. 2005.
Serné, E.H., et al., Belangrijke wijziging van behandelrichtlijn ‘Diabetes mellitus type 2’. Nederlands Tijdschrift voor Geneeskunde, 2021. 165.
Shah, B.M., P. Modi, and P. Trivedi, Recent medicinal chemistry approach for the development of dipeptidyl peptidase IV inhibitors. Current Medicinal Chemistry, 2021. 28(18): p. 3595-3621.
Xie, Z., et al., Synthesis, biological evaluation, and molecular docking studies of novel isatin-thiazole derivatives as α-glucosidase inhibitors. Molecules, 2017. 22(4): p. 659.
Tang, H., et al., Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities. Bioorganic & medicinal chemistry letters, 2010. 20(20): p. 6088-6092.
Li, F., et al., Design, synthesis, and pharmacological evaluation of N-(4-mono and 4, 5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl) propanamides as glucokinase activators. Bioorganic & medicinal chemistry, 2010. 18(11): p. 3875-3884.
Wang, G., et al., Synthesis, biological evaluation, and docking studies of novel 5, 6-diaryl-1, 2, 4-triazine thiazole derivatives as a new class of α-glucosidase inhibitors. Bioorganic Chemistry, 2018. 78: p. 195-200.
Iqbal, A.M., et al., Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole/triazole/oxadiazole ring. European journal of medicinal chemistry, 2012. 53: p. 308-315.
Gao, H.-D., et al., Sulfonamide-1, 3, 5-triazine–thiazoles: discovery of a novel class of antidiabetic agents via inhibition of DPP-4. RSC advances, 2016. 6(86): p. 83438-83447.
Gümüş, M., M. Yakan, and İ. Koca, Recent advances of thiazole hybrids in biological applications. Future Medicinal Chemistry, 2019. 11(16): p. 1979-1998.
Ibrahim, S.A. and H.F. Rizk, Synthesis and biological evaluation of thiazole derivatives, in Azoles-Synthesis, Properties, Applications and Perspectives. 2020, IntechOpen.
Li, Z., et al., Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold. Bioorganic Chemistry, 2018. 77: p. 429-435.
Li, Z., et al., Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents. European Journal of Medicinal Chemistry, 2019. 164: p. 352-365.
Li, Z., et al., ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis. Pharmacological Research, 2020. 159: p. 105035.
Li, Z., et al., Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents. Bioorganic Chemistry, 2019. 92: p. 103254.
Falomir-Lockhart, L.J., et al., Fatty acid signaling mechanisms in neural cells: fatty acid receptors. Frontiers in cellular neuroscience, 2019. 13: p. 162.
Shiradkar, M.R., et al., A novel approach to cyclin-dependent kinase 5/p25 inhibitors: A potential treatment for Alzheimer’s disease. Bioorganic & medicinal chemistry, 2007. 15(19): p. 6397-6406.
Siddiqui, N., et al., International Journal of Drug Development & Research| October-December 2011| Vol. 3| Issue 4| ISSN 0975-9344| Available online http://www. ijddr. in Covered in Official Product of Elsevier, The Netherlands© 2010 IJDDR. Int. J. Drug Dev. & Res, 2011. 3(4): p. 156-164.
Khatik, G.L., et al., A retrospect study on thiazole derivatives as the potential antidiabetic agents in drug discovery and developments. Current drug discovery technologies, 2018. 15(3): p. 163-177.
Chen, K., et al., Thiazole-based and thiazolidine-based protein tyrosine phosphatase 1B inhibitors as potential anti-diabetes agents. Medicinal Chemistry Research, 2021. 30(3): p. 519-534.
Xu, Q., et al., Design, synthesis and biological evaluation of thiazole-and indole-based derivatives for the treatment of type II diabetes. European journal of medicinal chemistry, 2012. 52: p. 70-81.
Iida, T., et al., Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity. European Journal of Medicinal Chemistry, 2018. 158: p. 832-852.
Kitas, E., et al., Sulfonylureido thiazoles as fructose-1, 6-bisphosphatase inhibitors for the treatment of Type-2 diabetes. Bioorganic & medicinal chemistry letters, 2010. 20(2): p. 594-599.
King, A.J., The use of animal models in diabetes research. British journal of pharmacology, 2012. 166(3): p. 877-894.
King, A. and J. Bowe, Animal models for diabetes: understanding the pathogenesis and finding new treatments. Biochemical pharmacology, 2016. 99: p. 1-10.
Mayer, G. and P.V. Taberner, Effects of the imidazoline ligands efaroxan and KU14R on blood glucose homeostasis in the mouse. European Journal of Pharmacology, 2002. 454(1): p. 95-102.
Lin, M.H., et al., Identification of morin as an agonist of imidazoline I-3 receptor for insulin secretion in diabetic rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017. 390(10): p. 997-1003.
Wang, C.-Z., et al., 5-amino-imidazole carboxamide riboside acutely potentiates glucose-stimulated insulin secretion from mouse pancreatic islets by KATP channel-dependent and-independent pathways. Biochemical and biophysical research communications, 2005. 330(4): p. 1073-1079.
Szkudelski, T. and K. Szkudelska, The relevance of AMP-activated protein kinase in insulin-secreting β cells: a potential target for improving β cell function? Journal of physiology and biochemistry, 2019. 75(4): p. 423-432.
Narasimhan, B., D. Sharma, and P. Kumar, Biological importance of imidazole nucleus in the new millennium. Medicinal Chemistry Research, 2011. 20(8): p. 1119-1140.
Nyblom, H.K., E. Sargsyan, and P. Bergsten, AMP-activated protein kinase agonist dose dependently improves function and reduces apoptosis in glucotoxic b-cells without changing triglyceride levels. Journal of Molecular Endocrinology, 2008. 41: p. 187-194.
McKiney, J.M., et al., Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal β-cells. 2010.
Langelueddecke, C., et al., Effect of the AMP-kinase modulators AICAR, metformin and compound C on insulin secretion of INS-1E rat insulinoma cells under standard cell culture conditions. Cellular Physiology and Biochemistry, 2012. 29(1-2): p. 75-86.
Rutter, G.A., et al., Pancreatic β-cell identity, glucose sensing and the control of insulin secretion. Biochemical Journal, 2015. 466(2): p. 203-218.
Crane, L., et al., Design and synthesis of novel imidazoline derivatives with potent antihyperglycemic activity in a rat model of type 2 diabetes. Bioorganic & medicinal chemistry, 2006. 14(22): p. 7419-7433.
Han, M.S. and D.H. Kim, Effect of zinc ion on the inhibition of carboxypeptidase A by imidazole-bearing substrate analogues. Bioorganic & medicinal chemistry letters, 2001. 11(11): p. 1425-1427.
Minoura, H., et al., Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. European journal of pharmacology, 2004. 494(2-3): p. 273-281.
Sime, M., et al., Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist. Bioorganic & medicinal chemistry letters, 2011. 21(18): p. 5568-5572.
Goebel, M., et al., Characterization of new PPARγ agonists: benzimidazole derivatives–the importance of position 2. ChemMedChem: Chemistry Enabling Drug Discovery, 2009. 4(7): p. 1136-1142.
Casimiro-Garcia, A., et al., Discovery of a series of imidazo [4, 5-b] pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ. Journal of medicinal chemistry, 2011. 54(12): p. 4219-4233.
Kouskoumvekaki, I., et al., Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow. Journal of chemical information and modeling, 2013. 53(4): p. 923-937.
Kurukulasuriya, R., et al., Prospects for pharmacologic inhibition of hepatic glucose production. Current medicinal chemistry, 2003. 10(2): p. 99-121.
Goyard, D., et al., Glucose-based spiro-oxathiazoles as in vivo anti-hyperglycemic agents through glycogen phosphorylase inhibition. Organic & Biomolecular Chemistry, 2020. 18(5): p. 931-940.
Liang, Y., et al., Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes, 2004. 53(2): p. 410-417.
Sloop, K.W., et al., Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. The Journal of clinical investigation, 2004. 113(11): p. 1571-1581.
Biftu, T., et al., (3R)-4-[(3R)-3-Amino-4-(2, 4, 5-trifluorophenyl) butanoyl]-3-(2, 2, 2-trifluoroethyl)-1, 4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorganic & medicinal chemistry letters, 2007. 17(1): p. 49-52.
Kim, R.M., et al., Discovery of potent, orally active benzimidazole glucagon receptor antagonists. Bioorganic & medicinal chemistry letters, 2008. 18(13): p. 3701-3705.
Printz, R.L., M.A. Magnuson, and D.K. Granner, Mammalian glucokinase. Annual review of nutrition, 1993. 13(1): p. 463-496.
Petersen, K. and J. Sullivan, Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans. Diabetologia, 2001. 44(11): p. 2018-2024.
Wallace, M.B., et al., Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorganic & medicinal chemistry letters, 2008. 18(7): p. 2362-2367.
Matschinsky, F.M., A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes, 1996. 45(2): p. 223-241.
Matschinsky, F.M., B. Glaser, and M.A. Magnuson, Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes, 1998. 47(3): p. 307-315.
Sarabu, R. and J. Grimsby, Targeting glucokinase activation for the treatment of type 2 diabetes--a status review. Current opinion in drug discovery & development, 2005. 8(5): p. 631-637.
Castelhano, A.L., et al., Glucokinase-activating ureas. Bioorganic & Medicinal chemistry letters, 2005. 15(5): p. 1501-1504.
McKerrecher, D., et al., Discovery, synthesis and biological evaluation of novel glucokinase activators. Bioorganic & medicinal chemistry letters, 2005. 15(8): p. 2103-2106.
Kumar, J.A., et al., New antihyperglycemic, α-glucosidase inhibitory, and cytotoxic derivatives of benzimidazoles. Journal of enzyme inhibition and medicinal chemistry, 2010. 25(1): p. 80-86.
Drucker, D.J. and M.A. Nauck, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet, 2006. 368(9548): p. 1696-1705.
Herman, G.A., et al., Pharmacokinetics and pharmacodynamic effects of the oral DPP‐4 inhibitor sitagliptin in middle‐aged obese subjects. The Journal of Clinical Pharmacology, 2006. 46(8): p. 876-886.
Ahrén, B., et al., Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes care, 2004. 27(12): p. 2874-2880.
Miyamoto, Y., et al., Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125. Bioorganic & medicinal chemistry, 2011. 19(1): p. 172-185.
Lam, B., et al., Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors. Bioorganic & medicinal chemistry letters, 2012. 22(21): p. 6628-6631.
Kondo, T., et al., Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group. Bioorganic & medicinal chemistry, 2008. 16(4): p. 1613-1631.
Rathi, A.K., et al., Piperazine derivatives for therapeutic use: a patent review (2010-present). Expert opinion on therapeutic patents, 2016. 26(7): p. 777-797.
Lan, H., et al., GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. Journal of Endocrinology, 2009. 201(2): p. 219.
Blad, C.C., C. Tang, and S. Offermanns, G protein-coupled receptors for energy metabolites as new therapeutic targets. Nature reviews Drug discovery, 2012. 11(8): p. 603-619.
Boyle, C.D., et al., Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders. 2013, Google Patents.
Pilkis, S.J. and D. Granner, Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annual review of physiology, 1992. 54(1): p. 885-909.
Gerich, J.E., et al., Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes care, 2001. 24(2): p. 382-391.
Shah, A.M. and F.E. Wondisford, Tracking the carbons supplying gluconeogenesis. Journal of Biological Chemistry, 2020. 295(42): p. 14419-14429.
Ramesh, B. and K. Pugalendi, Antihyperglycemic effect of umbelliferone in streptozotocin-diabetic rats. Journal of medicinal food, 2006. 9(4): p. 562-566.
Ji, H., et al., Synthesis and anticancer activity of new coumarin-3-carboxylic acid derivatives as potential lactate transport inhibitors. Bioorganic & Medicinal Chemistry, 2021. 29: p. 115870.
Zhang, X., et al., Unraveling the regulation of hepatic gluconeogenesis. Front Endocrinol. 2019; 9. 2018.
Ranđelović, S. and R. Bipat, A Review of Coumarins and Coumarin-Related Compounds for Their Potential Antidiabetic Effect. Clinical Medicine Insights: Endocrinology and Diabetes, 2021. 14: p. 11795514211042023.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Manjeela Subba MANJEELA, Shubam Nain, Gurvinder Singh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
+91-8349444385,
+91-8670408670,
